Wedemeyer, H. Et Al. 2023. Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study. International Liver Congress , (Vienna, Austria).

Wedemeyer, H., Gane, E. J., Agarwal, K., Tabak, F., Forns, X., AKARCA, U. S., ... Viacheslav, M.(2023). Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study . International Liver Congress, Vienna, Austria

Wedemeyer, Heiner Et Al. "Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study," International Liver Congress, Vienna, Austria, 2023

Wedemeyer, Heiner Et Al. "Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study." International Liver Congress , Vienna, Austria, 2023

Wedemeyer, H. Et Al. (2023) . "Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study." International Liver Congress , Vienna, Austria.

@conferencepaper{conferencepaper, author={Heiner Wedemeyer Et Al. }, title={Treatment with siRNA JNJ-73763989 plus nucleos (t)ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study}, congress name={International Liver Congress}, city={Vienna}, country={Austria}, year={2023}}